<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: accumulated deficit", fill: "#4997d0"},
{source: "2: accumulated deficit", target: "2: December ", fill: "#4997d0"},
{source: "2: accumulated deficit", target: "4: net loss applicable", fill: "#23297a"},
{source: "4: net loss applicable", target: "4: shareholders", fill: "#23297a"},
{source: "4: shareholders", target: "4: December ", fill: "#23297a"},
{source: "4: net loss applicable", target: "9: consistent profitable level", fill: "#f28500"},
{source: "9: consistent profitable level", target: "9: operations will", fill: "#f28500"},
{source: "9: operations will", target: "9: dependent", fill: "#f28500"},
{source: "9: dependent", target: "9: effective promotional strategy", fill: "#f28500"},
{source: "9: effective promotional strategy", target: "9: Acthar ", fill: "#f28500"},
{source: "9: Acthar ", target: "9: additional commercial products", fill: "#f28500"},
{source: "9: additional commercial products", target: "9: finance operations until consistent", fill: "#f28500"},
{source: "9: finance operations until consistent", target: "9: cash flows", fill: "#f28500"},
{source: "9: cash flows", target: "9: contract manufacturers on", fill: "#f28500"},
{source: "9: contract manufacturers on", target: "9: timely basis", fill: "#f28500"},
{source: "9: timely basis", target: "9: customers compliance with", fill: "#f28500"},
{source: "9: customers compliance with", target: "9: product return", fill: "#f28500"},
{source: "9: consistent profitable level", target: "10: generate sufficient revenues from sales", fill: "#367588"},
{source: "10: generate sufficient revenues from sales", target: "10: profitability", fill: "#367588"},
{source: "10: profitability", target: "10: operations", fill: "#367588"},
{source: "10: generate sufficient revenues from sales", target: "56: future capital requirements will depend on", fill: "#014421"},
{source: "56: future capital requirements will depend on", target: "56: existing product sales performance", fill: "#014421"},
{source: "56: existing product sales performance", target: "56: successfully implementing", fill: "#014421"},
{source: "56: successfully implementing", target: "56: growth strategy", fill: "#014421"},
{source: "56: growth strategy", target: "56: efficiencies", fill: "#014421"},
{source: "56: efficiencies", target: "56: customer compliance with", fill: "#014421"},
{source: "56: customer compliance with", target: "56: product from", fill: "#014421"},
{source: "56: product from", target: "56: additional products", fill: "#014421"},
{source: "56: future capital requirements will depend on", target: "88: Additionally ", fill: "#30ba8f"},
{source: "88: Additionally ", target: "88: management", fill: "#30ba8f"},
{source: "88: Additionally ", target: "89: staffing levels", fill: "#bd33a4"},
{source: "89: staffing levels", target: "89: management", fill: "#bd33a4"},
{source: "89: management", target: "89: operational personnel", fill: "#bd33a4"},
{source: "89: operational personnel", target: "89: marketing financial operations", fill: "#bd33a4"},
{source: "89: marketing financial operations", target: "89: development", fill: "#bd33a4"},
{source: "89: development", target: "89: regulatory", fill: "#bd33a4"},
{source: "89: regulatory", target: "89: assurance medical affairs", fill: "#bd33a4"},
{source: "89: assurance medical affairs", target: "89: manufacturing", fill: "#bd33a4"},
{source: "89: manufacturing", target: "89: future will also", fill: "#bd33a4"},
{source: "89: staffing levels", target: "108: technology", fill: "#efdecd"},
{source: "108: technology", target: "108: controlled by third parties", fill: "#efdecd"},
{source: "108: controlled by third parties", target: "108: advantageous", fill: "#efdecd"},
{source: "108: advantageous", target: "108: licensed by competitors", fill: "#efdecd"},
{source: "108: licensed by competitors", target: "108: ours preventing us from", fill: "#efdecd"},
{source: "108: ours preventing us from", target: "108: technology on", fill: "#efdecd"},
{source: "108: technology", target: "START_HERE", fill: "#efdecd"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Defy norms</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December">December</a></td>
      <td>December is the twelfth and the final month of the year in the Julian and Gregorian calendars. It is also the last of seven months to have a length of 31 days.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_17">December 17</a></td>
      <td>December 17 is the 351st day of the year (352nd in leap years) in the Gregorian calendar;  14 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n497 BC – The first Saturnalia festival was celebrated in ancient Rome.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_18">December 18</a></td>
      <td>December 11 is the 345th day of the year (346th in leap years) in the Gregorian calendar;  20 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n220 – Emperor Xian of Han is forced to abdicate the throne by Cao Cao's son Cao Pi, ending the Han dynasty.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_1">December 1</a></td>
      <td>December is the twelfth and the final month of the year in the Julian and Gregorian calendars. It is also the last of seven months to have a length of 31 days.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2016_in_aviation">2016 in aviation</a></td>
      <td>This is a list of aviation-related events from 2016.\n\n\n== Events ==\n\n\n=== January ===\nThe Government of Italy permitted United States unmanned aerial vehicles (UAVs or drones) to fly strike missions from Naval Air Station Sigonella in Sicily where the US has operated unarmed surveillance UAVs since 2001 against Islamic State targets in Libya, but only if they are "defensive," protecting U.S. forces or rescuers retrieving downed pilots.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_8">December 8</a></td>
      <td>December 3 is the 337th day of the year (338th in leap years) in the Gregorian calendar;  28 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n915 – Pope John X crowns Berengar I of Italy as Holy Roman Emperor (probable date).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_1924_German_federal_election">December 1924 German federal election</a></td>
      <td>Federal elections were held in Germany on 7 December 1924, the second that year after the Reichstag had been dissolved on 20 October. The Social Democratic Party remained the largest party in the Reichstag, receiving an increased share of the vote and winning 131 of the 493 seats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_26">December 26</a></td>
      <td>December 15 is the 349th day of the year (350th in leap years) in the Gregorian calendar;  16 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n533 – Vandalic War: Byzantine general Belisarius defeats the Vandals, commanded by King Gelimer, at the Battle of Tricamarum.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Risk_management">Risk management</a></td>
      <td>Risk management is the identification, evaluation, and prioritization of risks (defined in ISO 31000 as the effect of uncertainty on objectives) followed by coordinated and economical application of resources to minimize, monitor, and control the probability or impact of unfortunate events or to maximize the realization of opportunities.\nRisks can come from various sources including uncertainty in international markets, threats from project failures (at any phase in design, development, production, or sustaining of life-cycles), legal liabilities, credit risk, accidents, natural causes and disasters, deliberate attack from an adversary, or events of uncertain or unpredictable root-cause.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Management">Management</a></td>
      <td>Management (or managing) is the administration of an organization, whether it is a business, a non-profit organization, or a government body. It is the art and science of managing resources of the business.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Agile_management">Agile management</a></td>
      <td>Agile management is the application of the principles of Agile software development to various management processes, particularly project management. Following the appearance of the Manifesto for Agile Software Development in 2001, Agile techniques started to spread into other areas of activity.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Network_management">Network management</a></td>
      <td>Network management is the process of administering and managing computer networks. Services provided by this discipline include fault analysis, performance management, provisioning of networks and maintaining quality of service.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sport_management">Sport management</a></td>
      <td>Sport management is the field of business dealing with sports and recreation. Sports management involves any combination of skills that correspond with planning, organizing, directing, controlling, budgeting, leading, or evaluating of any organization or business within the sports field.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Women_Management">Women Management</a></td>
      <td>Women Management is a modeling agency based in New York. Founded by Paul Rowland in 1988,  Women also has two sister agencies, Supreme Management and Women 360 Management, which is also part of the Women International Agency Chain.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_management">Emergency management</a></td>
      <td>Emergency management, also called emergency response or disaster management, is the organization and management of the resources and responsibilities for dealing with all humanitarian aspects of emergencies (prevention, preparedness, response, mitigation, and recovery). The aim is to prevent and reduce the harmful effects of all hazards, including disasters.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Test_management">Test management</a></td>
      <td>Test management most commonly refers to the activity of managing a testing process. A test management tool is software used to manage tests (automated or manual) that have been previously specified by a test procedure.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Educational_technology">Educational technology</a></td>
      <td>Educational technology (commonly abbreviated as edutech, or edtech) is the combined use of computer hardware, software, and educational theory and practice to facilitate learning. When referred to with its abbreviation, edtech, it is often referring to the industry of companies that create educational technology.In addition to practical educational experience, educational technology is based on theoretical knowledge from various disciplines such as communication, education, psychology, sociology, artificial intelligence, and computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_technology">Financial technology</a></td>
      <td>Financial technology (abbreviated fintech or FinTech) is the technology and innovation that aims to compete with traditional financial methods in the delivery of financial services. It is an emerging industry that uses technology to improve activities in finance.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology_company">Technology company</a></td>
      <td>A technology company (or tech company) is an electronics-based technological company, including, for example, business relating to digital electronics, software, and internet-related services, such as e-commerce services.\n\n\n== Details ==\nAccording to Fortune, as of 2020, the ten largest technology companies by revenue are: Apple Inc., Samsung, Foxconn, Alphabet Inc., Microsoft, Huawei, Dell Technologies, Hitachi, IBM, and Sony.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Space_technology">Space technology</a></td>
      <td>Space technology is technology for use in outer space, in travel (astronautics) or other activities beyond Earth's atmosphere, for purposes such as spaceflight, space exploration, and Earth observation. Space technology includes space vehicles such as spacecraft, satellites, space stations and orbital launch vehicles; deep-space communication; in-space propulsion; and a wide variety of other technologies including support infrastructure equipment, and procedures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bachelor_of_Technology">Bachelor of Technology</a></td>
      <td>A Bachelor of Technology (Latin Baccalaureus Technologiae, commonly abbreviated as B.Tech. or BTech; with honours as B.Tech.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>QUESTCOR PHARMACEUTICALS INC      Item 1A   Risk Factors       We have a history of operating losses and <font color="blue">may never generate sufficient</font>     revenue to achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We have a history of recurring operating losses, and our <font color="blue">accumulated deficit</font>     through  <font color="blue">December </font>31, 2005 was dlra79dtta1 million</td>
    </tr>
    <tr>
      <td>We recognized net income     applicable to <font color="blue">common <font color="blue">shareholders</font></font> for the year ended <font color="blue">December </font>31, 2005 of     dlra5dtta1 million, however, this included a one-time gain of dlra9dtta6 million on the     <font color="blue">divestment</font> of our non-core <font color="blue">product lines</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">net loss applicable</font> to common     <font color="blue">shareholders</font> was dlra1dtta5 million and dlra5dtta9 million for years ended <font color="blue">December </font>31,     2004 and 2003, respectively</td>
    </tr>
    <tr>
      <td>To date, our revenues have <font color="blue">been generated</font>     <font color="blue">principally from sales</font> of Acthar, Nascobal, Ethamolin, Glofil-125, Inulin     and VSL#3</td>
    </tr>
    <tr>
      <td>In October 2005, we sold the Nascobal, Ethamolin and Glofil-125     <font color="blue">product lines</font>, and <font color="blue">accordingly</font> we are <font color="blue">no longer selling such products</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">agreement</font> to promote VSL#3 expired in January 2005, and we are no longer     selling VSL#3</td>
    </tr>
    <tr>
      <td>We <font color="blue">discontinued selling</font> <font color="blue">Inulin in September </font>2003</td>
    </tr>
    <tr>
      <td>Our ability to achieve a <font color="blue">consistent</font>, profitable level of <font color="blue"><font color="blue">operations</font> will</font> be     <font color="blue">dependent</font> in large part upon our ability to:         •  develop, finance and implement an <font color="blue"><font color="blue">effective</font> promotional strategy</font> for     Acthar,         •  finance and acquire <font color="blue"><font color="blue">additional</font> <font color="blue">commercial products</font></font>,         •  <font color="blue">finance <font color="blue">operations</font> until <font color="blue">consistent</font></font> positive <font color="blue">cash flows</font> are achieved,         •  continue to receive finished product and API from our sole-source     <font color="blue">contract <font color="blue">manufacture</font>rs on</font> a <font color="blue">timely basis</font> and at acceptable costs,         •  continue to control our operating expenses, and          •   ensure  customers’ <font color="blue">compliance with</font> our sales and <font color="blue">product return</font>     policies</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">generate sufficient <font color="blue"><font color="blue">revenues from</font> sales</font></font> of Acthar, or if     we  are  unable  to  contain  costs  and  expenses, we may not achieve     <font color="blue">profitability</font> and may ultimately be unable to fund our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue"><font color="blue">revenues from</font> sales</font> of Acthar decline or fail to grow, we may not     have <font color="blue">sufficient revenues</font> to fund our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">currently rely exclusively on sales</font> of Acthar</td>
    </tr>
    <tr>
      <td>We expect to continue to     <font color="blue">rely on sales</font> of this product in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">review external</font>     <font color="blue">data sources</font> to estimate <font color="blue">customer demand</font> for Acthar</td>
    </tr>
    <tr>
      <td>In the event that     demand <font color="blue">for Acthar </font>is less than our sales to <font color="blue">wholesalers</font>, <font color="blue">excess inventory</font>     may result at the wholesaler level, which may impact future <font color="blue">product sales</font></td>
    </tr>
    <tr>
      <td>We  monitor  the  amount  of  Acthar at the <font color="blue">wholesale level as well as</font>     <font color="blue">prescription data</font> obtained <font color="blue">from <font color="blue">third party</font> sources</font> to <font color="blue">help assess product</font>     demand</td>
    </tr>
    <tr>
      <td>Although our goal is to <font color="blue">actively promote</font> Acthar, and we have no     reason to                                         8       _________________________________________________________________    [62]Table <font color="blue">of <font color="blue">Contents       </font></font>believe that our promotion of Acthar will not be successful, we cannot     <font color="blue">predict whether</font> the demand <font color="blue">for Acthar </font><font color="blue">will continue</font> in the future or that we     <font color="blue">will continue</font> to generate <font color="blue">significant</font> <font color="blue"><font color="blue">revenues from</font> sales</font> of Acthar</td>
    </tr>
    <tr>
      <td>We may     choose, in the future, to reallocate our sales and <font color="blue">promotion efforts</font> for     Acthar which may result in a decrease in <font color="blue">revenues from</font> this product</td>
    </tr>
    <tr>
      <td>If the     demand <font color="blue">for Acthar </font>declines, or if we are forced to reduce the price, or if     returns of <font color="blue">expired products</font> are <font color="blue">higher than</font> anticipated, or if we are forced     to re-negotiate contracts or terms, or if our customers do not <font color="blue">comply with</font>     our <font color="blue">existing policies</font>, our <font color="blue">revenues from</font> the sale of Acthar <font color="blue">would decline</font></td>
    </tr>
    <tr>
      <td>If the cost to produce Acthar increases, and we are unable to raise the     price  <font color="blue">correspondingly</font>,  our gross <font color="blue">margins on</font> the sale of Acthar would     decline</td>
    </tr>
    <tr>
      <td>If our <font color="blue">revenues from</font> the sale of Acthar decline or fail to grow,     our <font color="blue">total revenues</font>, gross margins and operating results would be harmed and     we may not have <font color="blue">sufficient revenues</font> to fund our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our  business  will be harmed if we are unable to implement our growth     <font color="blue">strategy <font color="blue">successfully</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">growth strategy</font> primarily</font> includes the <font color="blue">following components</font>:         •  <font color="blue">initially focusing</font> our <font color="blue">promotional efforts on</font> Acthar, our CNS product,         •  acquiring <font color="blue"><font color="blue">additional</font> <font color="blue">commercial products</font></font> that have <font color="blue">sales growth</font>     potential, are <font color="blue">promotionally responsive</font> to a focused and <font color="blue">targeted sales</font> and     marketing effort, complement our <font color="blue">therapeutic focus on neurology</font> and can be     acquired at a <font color="blue">reasonable valuation relative</font> to our cost of capital, and         •  developing <font color="blue">new medications focused</font> in CNS with our <font color="blue">corporate resources</font>     and <font color="blue">through corporate <font color="blue">collaborations</font></font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">failure on</font> our part to implement any or all of our <font color="blue">growth strategies</font>     <font color="blue"><font color="blue">successfully</font> would likely</font> have a material adverse effect on our financial     condition</td>
    </tr>
    <tr>
      <td>We have little or <font color="blue">no control over</font> our <font color="blue">wholesalers</font>’ buying patterns, which     may impact <font color="blue">future revenues</font>, returns and <font color="blue">excess inventory</font></td>
    </tr>
    <tr>
      <td>We sell Acthar <font color="blue">primarily through major drug <font color="blue">wholesalers</font> located</font> in the     <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td><font color="blue">Consistent </font>with the <font color="blue">pharmaceutical</font> industry, most of our     revenues  are  derived  from the <font color="blue">three largest drug <font color="blue">wholesalers</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">wholesalers</font> represented 87prca of our gross <font color="blue">product sales</font> for the year ended     <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>While we attempt to estimate <font color="blue">inventory levels</font> of <font color="blue">Acthar     </font>at the <font color="blue">three largest <font color="blue">wholesalers</font> using inventory data</font> obtained from them,     <font color="blue">historical prescription</font> information and <font color="blue">historical purchase patterns</font>, this     process is <font color="blue">inherently imprecise</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">rely solely upon</font> the <font color="blue">wholesalers</font> to     effect the <font color="blue"><font color="blue">distribution</font> allocation</font> of Acthar</td>
    </tr>
    <tr>
      <td>There can be no assurance that     these  <font color="blue">wholesalers</font>  will  <font color="blue">adequately</font>  manage  their local and regional     <font color="blue">inventories</font> to <font color="blue">avoid outages</font> or inventory build-ups</td>
    </tr>
    <tr>
      <td>On occasion we note     that the <font color="blue">wholesalers</font> buy quantities of product in excess of the quantities     being <font color="blue">sold by them</font>, resulting in increasing <font color="blue">inventories</font></td>
    </tr>
    <tr>
      <td>Acthar has an <font color="blue">expiration date</font> that is 18 months from date of <font color="blue">manufacture</font></td>
    </tr>
    <tr>
      <td>We     <font color="blue">will generally accept</font> for credit <font color="blue"><font color="blue">pharmaceutical</font> products returned within</font> the     <font color="blue">six month period following</font> the <font color="blue">expiration date</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">establish reserves</font> for     these credit <font color="blue">memoranda at</font> the time of sale</td>
    </tr>
    <tr>
      <td>There can be no assurance that     we will be able to <font color="blue">accurately forecast</font> the <font color="blue">reserve <font color="blue">requirements</font></font> needed to     provide for credit <font color="blue">memoranda issued</font> in the future</td>
    </tr>
    <tr>
      <td>Although our estimates     are <font color="blue">reviewed quarterly</font> for <font color="blue">reasonableness</font>, our <font color="blue">product return</font> activity could     <font color="blue">differ <font color="blue">significant</font>ly from</font> our estimates because our analyses of product     shipments, prescription trends and the amount of product in the <font color="blue">distribution</font>     channel  may not be accurate</td>
    </tr>
    <tr>
      <td>Actual <font color="blue">amounts could</font> be <font color="blue"><font color="blue">significant</font>ly <font color="blue">different from</font></font> the estimates     and <font color="blue">such differences</font> are accounted for in the period in which they become     known</td>
    </tr>
    <tr>
      <td>We do not control or <font color="blue"><font color="blue">significant</font>ly influence</font> the <font color="blue">purchasing patterns</font> of the     drug <font color="blue">wholesalers</font> who purchase Acthar</td>
    </tr>
    <tr>
      <td>These <font color="blue">wholesalers</font> are <font color="blue">sophisticated</font>     companies  that purchase our product in a <font color="blue">manner <font color="blue">consistent</font> with</font> their     <font color="blue">industry practices</font> and perceived business interests</td>
    </tr>
    <tr>
      <td>Our sales are subject     to the <font color="blue">purchase <font color="blue">requirements</font></font> of the major <font color="blue">wholesalers</font>, which, presumably,     are <font color="blue">based upon</font> their projected <font color="blue">demand levels</font></td>
    </tr>
    <tr>
      <td><font color="blue">Purchases </font>by any customer,     during any period, may be above or below <font color="blue">actual prescription volumes</font> of our     <font color="blue">product during</font> the <font color="blue">same period</font>, resulting in increases or <font color="blue">decreases</font> in     <font color="blue">product inventory existing</font> in the <font color="blue">distribution</font> channel</td>
    </tr>
    <tr>
      <td>We <font color="blue">provide reserves</font> for potentially excess, dated or <font color="blue">otherwise impaired</font>     inventory</td>
    </tr>
    <tr>
      <td><font color="blue">Reserves  </font>for  excess  finished  goods and work-in-process     <font color="blue">inventories</font> are based on an analysis of expected future sales that will     occur before the                                         9       _________________________________________________________________    [63]Table <font color="blue">of <font color="blue">Contents       </font></font><font color="blue">inventory on hand expires</font></td>
    </tr>
    <tr>
      <td>Reserves for raw material <font color="blue">inventories</font> are based     on viability and projected future use</td>
    </tr>
    <tr>
      <td>Judgment is required in estimating     reserves for excess or impaired <font color="blue">inventories</font></td>
    </tr>
    <tr>
      <td>Actual amounts of required     <font color="blue">reserves could</font> be <font color="blue">different from</font> the estimates and <font color="blue">such differences</font> are     accounted for in the period in which they <font color="blue">become known</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to <font color="blue">secure <font color="blue">additional</font> funding could lead</font> to a loss of your     <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>We anticipate that our <font color="blue">capital resources based on</font> our <font color="blue">internal forecasts</font> and     <font color="blue">projections will</font> be adequate to fund <font color="blue">operations</font> and <font color="blue">capital <font color="blue">expenditure</font>s</font>     <font color="blue">through at least</font> <font color="blue">December </font>31, 2006</td>
    </tr>
    <tr>
      <td>If we experience <font color="blue">unanticipated cash</font>     <font color="blue">requirements</font> and if revenues are less than we expect, we could be required     to <font color="blue">raise <font color="blue">additional</font> capital</font></td>
    </tr>
    <tr>
      <td>Regardless, we <font color="blue">may seek <font color="blue"><font color="blue">additional</font> funds</font></font> before     <font color="blue">December </font>31, 2006, through public or <font color="blue">private equity financing</font> or from other     sources</td>
    </tr>
    <tr>
      <td>Additionally, we may seek to <font color="blue">raise capital whenever <font color="blue">conditions</font></font> in     the <font color="blue">financial markets</font> are favorable, even if we do not have an immediate     need  for <font color="blue"><font color="blue">additional</font> cash at</font> that time</td>
    </tr>
    <tr>
      <td>There can be no assurance that     <font color="blue"><font color="blue">additional</font> funds</font> can be obtained <font color="blue">on desirable terms</font> or at all</td>
    </tr>
    <tr>
      <td>If <font color="blue">revenues from</font> <font color="blue">product sales</font> are less than we expect or if <font color="blue">further capital</font>     resources are not available, or if <font color="blue">such resources cannot</font> be obtained on     attractive  terms  to  us,  this <font color="blue">may further limit</font> our ability to fund     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our future capital <font color="blue">requirements</font> <font color="blue">will depend on</font> many factors,     including the following:         •  existing <font color="blue">product sales</font> performance,         •  <font color="blue"><font color="blue">successfully</font> implementing</font> our <font color="blue">growth strategy</font>,         •  achieving better operating <font color="blue">efficiencies</font>,         •  maintaining <font color="blue">customer <font color="blue">compliance with</font></font> our policies,         •  obtaining <font color="blue">product from</font> our sole-source contract <font color="blue">manufacture</font>rs, and         •  acquiring or developing <font color="blue"><font color="blue">additional</font> products</font></td>
    </tr>
    <tr>
      <td>We may obtain <font color="blue"><font color="blue">additional</font> financing through public</font> or <font color="blue">private debt</font> or equity     <font color="blue">financings</font></td>
    </tr>
    <tr>
      <td>However, <font color="blue"><font color="blue">additional</font> financing may</font> not be available to us on     acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>Further, <font color="blue">additional</font> equity <font color="blue">financings</font> will be     dilutive to our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">sufficient capital</font> is not available, then     we may be required to reduce our <font color="blue">operations</font> or to delay, reduce the scope     of,  eliminate  or <font color="blue">divest one</font> or more of our products or <font color="blue">manufacturing</font>     efforts</td>
    </tr>
    <tr>
      <td>If we are unable to contract with <font color="blue">third party</font> contract <font color="blue">manufacture</font>rs, we may     be unable to meet the demand for our products and <font color="blue">lose <font color="blue">potential revenues</font></font></td>
    </tr>
    <tr>
      <td>We rely on contract <font color="blue">manufacture</font>rs to produce our <font color="blue">marketed product</font>, Acthar,     and  will  likely  do the same for other products that we may develop,     <font color="blue">commercialize</font> or acquire in the future</td>
    </tr>
    <tr>
      <td>Contract <font color="blue">manufacture</font>rs may not be     able to meet our needs <font color="blue">with respect</font> to timing, cost, quantity or quality</td>
    </tr>
    <tr>
      <td>All  our  <font color="blue">manufacture</font>rs are sole-source <font color="blue">manufacture</font>rs and <font color="blue">no currently</font>     <font color="blue">qualified alternative suppliers</font> exist</td>
    </tr>
    <tr>
      <td>If  we  are unable to contract for a <font color="blue">sufficient supply</font> of our required     products and <font color="blue">services on</font> acceptable terms, or if we <font color="blue">should encounter delays</font>     or <font color="blue">difficulties</font> in our <font color="blue">relationships with</font> our <font color="blue">manufacture</font>rs, or if the     required <font color="blue">approvals by</font> the FDA and other <font color="blue"><font color="blue">regulatory</font> authorities</font> do not occur     on a <font color="blue">timely basis</font>, we <font color="blue">will lose sales</font></td>
    </tr>
    <tr>
      <td>Moreover, contract <font color="blue">manufacture</font>rs that     we may use must continually adhere to current good <font color="blue">manufacturing</font> practices     <font color="blue">enforced by</font> the FDA If the <font color="blue">facilities</font> of these <font color="blue">manufacture</font>rs cannot pass an     inspection, we may lose FDA approval of our products</td>
    </tr>
    <tr>
      <td>Failure to obtain     products for sale for any <font color="blue">reason may</font> result in an <font color="blue">inability</font> to <font color="blue">meet product</font>     demand and a loss of <font color="blue">potential revenues</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue"><font color="blue">third party</font> <font color="blue">distributors</font></font> are unable to distribute our product or the     costs  to distribute our <font color="blue">product increases substantially</font>, we will lose     <font color="blue">potential revenues</font> and profits</td>
    </tr>
    <tr>
      <td>We  transferred  certain  product  <font color="blue">distribution</font>  functions,  including     <font color="blue">warehousing</font>,  shipping  and  quality  control  studies, to <font color="blue">third party</font>     <font color="blue">distributors</font></td>
    </tr>
    <tr>
      <td>The outsourcing of these functions is complex, and we may     experience <font color="blue">difficulties</font> at the <font color="blue">third party</font> contractor level that could     reduce, delay or <font color="blue">stop shipments</font> of our product</td>
    </tr>
    <tr>
      <td>If we                                         10       _________________________________________________________________    [64]Table <font color="blue">of <font color="blue">Contents       </font></font>encounter such <font color="blue">distribution</font> problems, our <font color="blue">product could</font> become unavailable     and we <font color="blue">could lose revenues</font>, or the costs to distribute our <font color="blue">product could</font>     become <font color="blue">higher than</font> we anticipated</td>
    </tr>
    <tr>
      <td>For the year ended <font color="blue">December </font>31, 2005, 87prca of our gross <font color="blue">product sales</font> were     derived  from  the  <font color="blue">three largest drug <font color="blue">wholesalers</font></font></td>
    </tr>
    <tr>
      <td>Two of these three     <font color="blue">wholesalers</font> mandate a <font color="blue">distribution</font> fee for handling our product</td>
    </tr>
    <tr>
      <td>If other     <font color="blue">wholesalers</font> institute similar fees, or if such fees increase in magnitude in     the future, our costs to distribute our product will increase, and our gross     profit margins will decline</td>
    </tr>
    <tr>
      <td>We have experienced changes in <font color="blue">key personnel which will</font> have an uncertain     impact on future <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">On February </font>18, 2005, Mr</td>
    </tr>
    <tr>
      <td><font color="blue">James L Fares </font>was named President and Chief     Executive Officer, succeeding Mr</td>
    </tr>
    <tr>
      <td><font color="blue">Charles J Casamento </font>who resigned as     Chairman,  President and Chief Executive Officer on August 5, 2004</td>
    </tr>
    <tr>
      <td><font color="blue">Steve Cartt </font>was named <font color="blue">Executive Vice President </font>of     <font color="blue">Commercial Development</font></td>
    </tr>
    <tr>
      <td>We are highly <font color="blue">dependent</font> on the services of our     President and Chief Executive Officer, Mr</td>
    </tr>
    <tr>
      <td><font color="blue">James L Fares </font>and our Executive     Vice President of <font color="blue">Commercial Development</font>, Mr</td>
    </tr>
    <tr>
      <td><font color="blue">Fares or Mr</font></td>
    </tr>
    <tr>
      <td>Cartt <font color="blue">as employees</font>, our business could be harmed</td>
    </tr>
    <tr>
      <td>We do not carry key person <font color="blue">life insurance</font> for our <font color="blue">senior <font color="blue">management</font></font> or other     personnel</td>
    </tr>
    <tr>
      <td>Additionally, the future potential growth and expansion of our     business is expected to place increased demands on our <font color="blue">management</font> skills and     resources</td>
    </tr>
    <tr>
      <td>Although some changes in <font color="blue">staffing levels</font> are expected during     2006, recruiting and retaining <font color="blue">management</font> and <font color="blue">operational personnel</font> to     perform sales and marketing, financial <font color="blue">operations</font>, business <font color="blue">development</font>,     <font color="blue">regulatory</font>  affairs,  quality  assurance, medical affairs and contract     <font color="blue">manufacturing</font> in the <font color="blue">future will also</font> be critical to our success</td>
    </tr>
    <tr>
      <td>We do not     know  if we will be able to attract and retain skilled and experienced     <font color="blue">management</font> and <font color="blue">operational personnel</font> in the future on acceptable <font color="blue">terms given</font>     the <font color="blue">intense competition among numerous <font color="blue">pharmaceutical</font></font> and <font color="blue">bio<font color="blue">technology</font></font>     companies for <font color="blue">such personnel</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">hire <font color="blue">necessary</font> skilled</font>     personnel in the future, our business could be harmed</td>
    </tr>
    <tr>
      <td>Our <font color="blue">products may</font> not be <font color="blue">accepted by</font> the market, which may result in lower     <font color="blue"><font color="blue">future revenues</font> as well as</font> a decline in our <font color="blue"><font color="blue">competitive position</font>ing</font></td>
    </tr>
    <tr>
      <td>Acthar and any products that we <font color="blue">successfully</font> acquire or develop in the     future, if approved for marketing, may never achieve <font color="blue">market <font color="blue">acceptance</font></font></td>
    </tr>
    <tr>
      <td>These products, if <font color="blue">successfully</font> developed, <font color="blue">will <font color="blue">compete with</font> drugs</font> and     therapies  <font color="blue">manufacture</font>d and <font color="blue">marketed by major <font color="blue">pharmaceutical</font></font> and other     <font color="blue">bio<font color="blue">technology</font></font> companies</td>
    </tr>
    <tr>
      <td>Physicians, patients or the <font color="blue">medical community</font> in     <font color="blue">general may</font> not accept and utilize the products that we may develop or that     our <font color="blue"><font color="blue">corporate partners</font> may</font> develop</td>
    </tr>
    <tr>
      <td>The degree of <font color="blue">market <font color="blue">acceptance</font></font> of our <font color="blue">commercial products</font> and any products     that we <font color="blue">successfully</font> develop <font color="blue">will depend on</font> a number of factors, including:         •  the <font color="blue">establishment</font> and <font color="blue">demonstration</font> of the <font color="blue">clinical efficacy</font> and safety     of the <font color="blue">product candidates</font>,          •  their potential advantage over alternative treatment methods and     <font color="blue">competing products</font>,         •  <font color="blue"><font color="blue">reimbursement</font> policies</font> of <font color="blue">government</font> and <font color="blue">third party</font> payors, and         •  our ability to market and promote the <font color="blue">products <font color="blue">effective</font>ly</font></td>
    </tr>
    <tr>
      <td>The failure of our products to achieve <font color="blue">market <font color="blue">acceptance</font></font> may result in lower     <font color="blue"><font color="blue">future revenues</font> as well as</font> a decline in our <font color="blue"><font color="blue">competitive position</font>ing</font></td>
    </tr>
    <tr>
      <td>A large percentage of our <font color="blue">voting stock</font> is <font color="blue">beneficially</font> owned by a small     number of <font color="blue">stockholders</font>, who in the <font color="blue">future could attempt</font> to take control of     our <font color="blue">management</font> and <font color="blue">operations</font> or <font color="blue">exercise <font color="blue">voting power</font></font> to advance their own     <font color="blue">best interests</font> and not <font color="blue">necessarily</font> those of other <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>As  of <font color="blue">December </font>31, 2005, Sigma-Tau Finanziaria SpA and its <font color="blue">affiliates</font>     (“Sigma-Tau”) <font color="blue">beneficially</font> owned, directly or indirectly, approximately 21prca     of  the <font color="blue">voting power</font> of our <font color="blue">outstanding voting capital stock</font>, and they     <font color="blue">beneficially</font>  owned approximately 25prca of our <font color="blue">outstanding <font color="blue">common stock</font></font></td>
    </tr>
    <tr>
      <td>Additionally, we have other <font color="blue">stockholders</font> who own <font color="blue"><font color="blue">significant</font> amounts</font> of our     voting capital stock, as reported on various Schedule 13D’s filed with the                                         11       _________________________________________________________________    [65]Table <font color="blue">of <font color="blue">Contents       </font></font>Securities and Exchange Commission</td>
    </tr>
    <tr>
      <td>Accordingly, these <font color="blue">stockholders</font>, acting     <font color="blue">individually</font> or together, could control the outcome of <font color="blue">certain shareholder</font>     votes, including <font color="blue">votes concerning</font> the election of <font color="blue">directors</font>, the adoption or     <font color="blue">amendment</font> of provisions in our Articles of Incorporation, and the approval     of <font color="blue"><font color="blue">significant</font> corporate transactions</font></td>
    </tr>
    <tr>
      <td>This level of <font color="blue">concentrated ownership</font>     may, at a minimum, have the effect of delaying or preventing a change in the     <font color="blue">management</font> or <font color="blue">voting control</font> of us by a <font color="blue">third party</font></td>
    </tr>
    <tr>
      <td>It may also place us in     the position of having these large <font color="blue">stockholders</font> take control of us and     having new <font color="blue">management</font> inserted and <font color="blue">new objectives adopted</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">competitors</font> develop and <font color="blue">market products</font> that are more <font color="blue"><font color="blue">effective</font> than</font>     ours, our <font color="blue">commercial opportunity will</font> be reduced or eliminated</td>
    </tr>
    <tr>
      <td>The <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> industries are <font color="blue">intensely competitive</font>     and subject to rapid and <font color="blue"><font color="blue">significant</font> technological</font> change</td>
    </tr>
    <tr>
      <td>A number of     companies are pursuing the <font color="blue">development</font> of <font color="blue">pharmaceutical</font>s and products that     target the <font color="blue">same diseases</font> and <font color="blue">conditions</font> that we target</td>
    </tr>
    <tr>
      <td>For example, there     are <font color="blue">products on</font> the market that <font color="blue">compete with</font> Acthar</td>
    </tr>
    <tr>
      <td>Moreover, <font color="blue">technology</font>     <font color="blue"><font color="blue">controlled by</font> <font color="blue">third parties</font></font> that may be <font color="blue">advantageous</font> to our business may be     acquired or licensed by <font color="blue">competitors</font> of ours, preventing us from obtaining     this <font color="blue">technology</font> on favorable terms, or at all</td>
    </tr>
    <tr>
      <td>Our ability to compete <font color="blue">will depend on</font> our ability to create and maintain     <font color="blue">scientifically</font>  advanced  <font color="blue">technology</font>,  and  to  develop,  acquire  and     <font color="blue">commercialize</font> <font color="blue">pharmaceutical</font> products based on this <font color="blue">technology</font>, as well as     our  ability  to attract and retain <font color="blue">qualified personnel</font>, obtain patent     protection, or otherwise develop <font color="blue">proprietary</font> <font color="blue">technology</font> or processes, and     secure <font color="blue">sufficient capital</font> resources for the expected substantial time period     <font color="blue">between technological conception</font> and <font color="blue"><font color="blue">commercial sale</font>s</font> of products <font color="blue">based upon</font>     our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Many of the companies developing <font color="blue">competing <font color="blue">technologies</font></font> and products have     <font color="blue"><font color="blue">significant</font>ly greater financial resources</font> and expertise in <font color="blue">development</font>,     <font color="blue">manufacturing</font>, obtaining <font color="blue">regulatory</font> approvals, and <font color="blue">marketing than</font> we do</td>
    </tr>
    <tr>
      <td>Other  <font color="blue">smaller companies may also prove</font> to be <font color="blue">significant</font> <font color="blue">competitors</font>,     <font color="blue">particularly through <font color="blue">collaborative arrangements</font> with</font> large and established     companies</td>
    </tr>
    <tr>
      <td><font color="blue">Academic </font>institutions, <font color="blue">government</font> agencies and other public and private     research  <font color="blue">organizations</font>  <font color="blue">may also seek patent protection</font> and establish     <font color="blue">collaborative arrangements</font> for clinical <font color="blue">development</font>, <font color="blue">manufacturing</font>, and     marketing of products similar to ours</td>
    </tr>
    <tr>
      <td>These companies and institutions will     <font color="blue">compete with</font> us in recruiting and retaining <font color="blue">qualified sales</font> and marketing     and <font color="blue">management</font> personnel, as well as in acquiring <font color="blue"><font color="blue">technologies</font> complementary</font>     to our programs</td>
    </tr>
    <tr>
      <td>We will face competition <font color="blue">with respect</font> to:         •  <font color="blue">product efficacy</font> and safety,         •  the timing and scope of <font color="blue">regulatory</font> approvals,         •  <font color="blue">availability</font> of resources,         •  price, and         •  <font color="blue">patent position</font>, including potentially dominant <font color="blue">patent position</font>s of     others</td>
    </tr>
    <tr>
      <td>If our <font color="blue">competitors</font> succeed in developing <font color="blue">technologies</font> and drugs that are     more <font color="blue">effective</font> or <font color="blue">less costly than</font> any that we develop or acquire, our     <font color="blue">technology</font> and <font color="blue">future drugs may</font> be rendered obsolete and <font color="blue">noncompetitive</font></td>
    </tr>
    <tr>
      <td>In     addition, our <font color="blue">competitors</font> may succeed in obtaining the approval of the FDA     or other <font color="blue">regulatory</font> approvals for <font color="blue"><font color="blue">drug candidate</font>s</font> more <font color="blue">rapidly than</font> we will</td>
    </tr>
    <tr>
      <td><font color="blue">Companies </font>that complete <font color="blue">clinical trials</font>, obtain required <font color="blue">regulatory</font> agency     approvals  and  commence  commercial  sale of their drugs before their     <font color="blue">competitors</font> may achieve a <font color="blue"><font color="blue">significant</font> competitive advantage</font>, including     patent and FDA <font color="blue">marketing <font color="blue">exclusivity</font> rights</font> that would delay our ability to     <font color="blue">market specific products</font></td>
    </tr>
    <tr>
      <td>We do not know if drugs resulting from the joint     efforts of our existing or <font color="blue">future collaborative partners will</font> be able to     compete <font color="blue">successfully</font> with our <font color="blue">competitors</font>’ existing products or products     under <font color="blue">development</font> or whether we will obtain <font color="blue">regulatory</font> approval in the     US or elsewhere</td>
    </tr>
    <tr>
      <td>12       _________________________________________________________________    [66]Table <font color="blue">of <font color="blue">Contents       </font></font>If we fail to maintain or <font color="blue">enter into new contracts</font> related to <font color="blue">collaborations</font>     and in-licensed or acquired <font color="blue">technology</font> and products, our product <font color="blue">development</font>     and <font color="blue"><font color="blue">commercialization</font> could</font> be delayed</td>
    </tr>
    <tr>
      <td>Our business model has been <font color="blue">dependent</font> on our ability to <font color="blue">enter into licensing</font>     and <font color="blue">acquisition arrangements with commercial</font> or <font color="blue">academic entities</font> to obtain     <font color="blue">technology</font> for <font color="blue">commercialization</font> or <font color="blue">marketed product</font>s</td>
    </tr>
    <tr>
      <td>If we are unable to     enter  into  any  new  <font color="blue">agreement</font>s  in  the future, our <font color="blue">development</font> and     <font color="blue">commercialization</font> efforts will be delayed</td>
    </tr>
    <tr>
      <td>Disputes may arise regarding the     <font color="blue">inventorship</font> and <font color="blue">corresponding rights</font> in <font color="blue">inventions</font> and know-how resulting     from  the <font color="blue">joint creation</font> or use of <font color="blue"><font color="blue">intellectual</font> property by us</font> and our     <font color="blue">licensors</font> or <font color="blue">scientific <font color="blue">collaborators</font></font></td>
    </tr>
    <tr>
      <td>We may not be able to negotiate     <font color="blue"><font color="blue">additional</font> license</font> and acquisition <font color="blue">agreement</font>s in the future on acceptable     terms, if at all</td>
    </tr>
    <tr>
      <td>In addition, current license and acquisition <font color="blue">agreement</font>s     may be terminated, and we may not be able to maintain the <font color="blue">exclusivity</font> of our     <font color="blue">exclusive licenses</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">collaborators</font> do not commit sufficient <font color="blue">development</font> resources, <font color="blue">technology</font>,     <font color="blue">regulatory</font> expertise, <font color="blue">manufacturing</font>, marketing and other <font color="blue">resources towards</font>     developing,  promoting  and <font color="blue"><font color="blue">commercializing products</font> incorporating</font> our     <font color="blue">discoveries</font>, the progress of our licensed products <font color="blue">development</font> will be     stalled</td>
    </tr>
    <tr>
      <td>Further, <font color="blue">competitive conflicts may</font> arise among these <font color="blue">third parties</font>     that <font color="blue">could prevent them from</font> working <font color="blue">cooperatively with us</font></td>
    </tr>
    <tr>
      <td>The amount and     timing of <font color="blue">resources devoted</font> to these <font color="blue"><font color="blue">activities</font> by</font> the parties could depend     on  the <font color="blue">achievement</font> of <font color="blue">milestones by us</font> and otherwise generally may be     <font color="blue">controlled by</font> other parties</td>
    </tr>
    <tr>
      <td>In addition, we expect that our <font color="blue">agreement</font>s with     future <font color="blue">collaborators</font> will likely permit the <font color="blue">collaborators</font> to terminate their     <font color="blue">agreement</font>s  upon  written notice to us</td>
    </tr>
    <tr>
      <td>This type of <font color="blue"><font color="blue">termination</font> would</font>     <font color="blue">substantially reduce</font> the likelihood that the <font color="blue">applicable research program</font> or     any <font color="blue">lead candidate</font> or <font color="blue">candidates would</font> be developed into a <font color="blue">drug candidate</font>,     would obtain <font color="blue">regulatory</font> approvals and would be <font color="blue">manufacture</font>d and <font color="blue">successfully</font>     <font color="blue">commercialize</font>d</td>
    </tr>
    <tr>
      <td>If  none  of  our  <font color="blue">collaborations</font>  are  successful  in  developing and     <font color="blue">commercializing products</font>, or if we do not receive <font color="blue">milestone payments</font> or     generate  <font color="blue">revenues from</font> royalties sufficient to offset our <font color="blue">significant</font>     <font color="blue">investment</font> in product <font color="blue">development</font> and other costs, then our business could     be harmed</td>
    </tr>
    <tr>
      <td>Dis<font color="blue">agreement</font>s with our <font color="blue">collaborators</font> could lead to delays or     interruptions in, or <font color="blue">termination</font> of, <font color="blue">development</font> and <font color="blue">commercialization</font> of     <font color="blue">certain potential products</font> or could require or result in <font color="blue">litigation</font> or     arbitration, which could be time-consuming and expensive and may result in     <font color="blue">lost revenues</font> and substantial <font color="blue">legal costs which could <font color="blue">negatively</font> impact</font> our     results  from <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, if we are unable to acquire new     <font color="blue">marketed product</font>s on a <font color="blue">timely basis</font> at an <font color="blue">appropriate purchase price</font> and     terms, we may not reach <font color="blue">profitability</font> and may not <font color="blue">generate sufficient cash</font>     to fund <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If  we  are  unable to protect our <font color="blue"><font color="blue">proprietary</font> rights</font>, we may lose our     <font color="blue">competitive position</font> and <font color="blue">future revenues</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font> in part on our ability to:         •  obtain patents for our products and <font color="blue">technologies</font>,         •  <font color="blue">protect trade secrets</font>,         •  operate <font color="blue">without infringing upon</font> the <font color="blue"><font color="blue">proprietary</font> rights</font> of others, and         •  <font color="blue">prevent others from infringing on</font> our <font color="blue"><font color="blue">proprietary</font> rights</font></td>
    </tr>
    <tr>
      <td>We will only be able to protect our <font color="blue"><font color="blue">proprietary</font> rights</font> from <font color="blue">unauthorized use</font>     by <font color="blue">third parties</font> to the extent that these rights are <font color="blue">covered by valid</font> and     <font color="blue">enforceable patents</font> or are <font color="blue">effective</font>ly maintained <font color="blue">as trade secrets</font> and are     <font color="blue">otherwise protectable under applicable law</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">will attempt</font> to protect our     <font color="blue">proprietary</font> position by filing US and foreign patent <font color="blue"><font color="blue">application</font>s</font> related     to our <font color="blue">proprietary</font> products, <font color="blue">technology</font>, <font color="blue">inventions</font> and <font color="blue">improvements</font> that     are important to the <font color="blue">development</font> of our business</td>
    </tr>
    <tr>
      <td>The  <font color="blue">patent position</font>s of <font color="blue">bio<font color="blue">technology</font></font> and bio<font color="blue">pharmaceutical</font> companies     <font color="blue">involve complex legal</font> and factual questions and, therefore, enforceability     cannot be <font color="blue">predicted with certainty</font></td>
    </tr>
    <tr>
      <td>Patents, if issued, may be challenged,     invalidated or <font color="blue">circumvented</font></td>
    </tr>
    <tr>
      <td>Thus, any patents that we own or license from     <font color="blue">third parties</font> may not provide any protection against <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td><font color="blue">Pending     </font>patent <font color="blue"><font color="blue">application</font>s</font> we may file in the future, or those we <font color="blue">may license from</font>     <font color="blue">third parties</font>, may not result in patents being issued</td>
    </tr>
    <tr>
      <td>Also, <font color="blue">patent rights</font>     may not provide us with <font color="blue">proprietary</font> protection or <font color="blue">competitive advantages</font>     against  <font color="blue">competitors</font>  with similar <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Furthermore, <font color="blue">others may</font>     in<font color="blue">dependent</font>ly develop similar <font color="blue">technologies</font> or duplicate any <font color="blue">technology</font> that     we have developed or we will                                         13       _________________________________________________________________    [67]Table <font color="blue">of <font color="blue">Contents       </font></font>develop</td>
    </tr>
    <tr>
      <td>The laws of some <font color="blue">foreign countries may</font> not protect our <font color="blue">intellectual</font>     <font color="blue">property rights</font> to the <font color="blue">same extent as</font> do the laws of the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>In addition to patents, we <font color="blue">rely on trade secrets</font> and <font color="blue">proprietary</font> know-how</td>
    </tr>
    <tr>
      <td>We  currently  seek  protection,  in part, <font color="blue">through <font color="blue">confidential</font>ity</font> and     <font color="blue">proprietary</font>  information  <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td>These <font color="blue">agreement</font>s may not provide     <font color="blue">meaningful protection</font> or <font color="blue">adequate remedies</font> for <font color="blue">proprietary</font> <font color="blue">technology</font> in the     event of <font color="blue">unauthorized use</font> or <font color="blue">disclosure</font> of <font color="blue">confidential</font> and <font color="blue">proprietary</font>     information</td>
    </tr>
    <tr>
      <td>The <font color="blue">parties may</font> not <font color="blue">comply with</font> or may breach these <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td>Furthermore,  our  trade  secrets may otherwise <font color="blue">become known</font> to, or be     in<font color="blue">dependent</font>ly developed by <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will further depend</font>, in part, on our ability to operate without     infringing the <font color="blue"><font color="blue">proprietary</font> rights</font> of others</td>
    </tr>
    <tr>
      <td>If our <font color="blue"><font color="blue">activities</font> infringe on</font>     patents owned by others, we <font color="blue">could incur</font> substantial costs in defending     ourselves in <font color="blue">suits brought against</font> a licensor or us</td>
    </tr>
    <tr>
      <td>Should our products or     <font color="blue">technologies</font> be found to <font color="blue">infringe on patents issued</font> to <font color="blue">third parties</font>, the     <font color="blue">manufacture</font>, use and sale of our <font color="blue">products could</font> be enjoined, and we could be     required to pay substantial damages</td>
    </tr>
    <tr>
      <td>In addition, we, in <font color="blue">connection with</font> the     <font color="blue">development</font> and use of our products and <font color="blue">technologies</font>, may be required to     obtain licenses to patents or other <font color="blue"><font color="blue">proprietary</font> rights</font> of <font color="blue">third parties</font>,     which may not be made <font color="blue">available on terms</font> acceptable to us, if at all</td>
    </tr>
    <tr>
      <td>Since we must obtain <font color="blue">regulatory</font> approval to market our products in the     <font color="blue">United States</font> and in <font color="blue">foreign jurisdictions</font>, we cannot <font color="blue">predict whether</font> or     when we will be permitted to <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>Any products that we develop are subject to <font color="blue">regulation by federal</font>, state and     local <font color="blue">government</font>al authorities in the <font color="blue">United States</font>, including the FDA, and     by similar agencies in other countries</td>
    </tr>
    <tr>
      <td>Any product that we develop must     receive all relevant <font color="blue">regulatory</font> approvals or <font color="blue">clearances</font> before it may be     marketed in a <font color="blue">particular country</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">regulatory</font> process, which includes     extensive  preclinical  studies and <font color="blue">clinical trials</font> of <font color="blue">each product</font> to     establish its safety and efficacy, is uncertain, can take many years, and     requires  the <font color="blue">expenditure</font> of substantial resources</td>
    </tr>
    <tr>
      <td>Data obtained from     preclinical   and  clinical  <font color="blue">activities</font>  are  susceptible  to  varying     <font color="blue">interpretations</font> that could delay, limit or prevent <font color="blue">regulatory</font> approval or     clearance</td>
    </tr>
    <tr>
      <td>In addition, delays or <font color="blue">rejections may</font> be encountered <font color="blue">based upon</font>     changes in <font color="blue">regulatory</font> policy during the period of product <font color="blue">development</font> and     the period of review of any <font color="blue">application</font> for <font color="blue">regulatory</font> approval or clearance     for a product</td>
    </tr>
    <tr>
      <td>Delays in obtaining <font color="blue">regulatory</font> approvals or <font color="blue">clearances</font> could:         •  stall the marketing, selling and <font color="blue">distribution</font> of any products that our     <font color="blue">corporate partners</font> or we develop,         •  impose <font color="blue">significant</font> <font color="blue">additional</font> costs on our <font color="blue">corporate partners</font> and us,         •  diminish any <font color="blue">competitive advantages</font> that we or our <font color="blue">corporate partners</font>     may attain, and         •  decrease our ability to receive royalties and <font color="blue">generate revenues</font> and     profits</td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font>approval, if granted, may entail <font color="blue">limitation</font>s on the indicated     uses for which a <font color="blue">new product may</font> be marketed that <font color="blue">could limit</font> the potential     market for the product</td>
    </tr>
    <tr>
      <td>Product approvals, once granted, may be withdrawn if     problems  occur after <font color="blue">initial marketing</font></td>
    </tr>
    <tr>
      <td>Furthermore, <font color="blue">manufacture</font>rs of     <font color="blue">approved products</font> are subject to <font color="blue">pervasive review</font>, including <font color="blue">compliance with</font>     <font color="blue">detailed <font color="blue">regulations</font> governing</font> FDA good <font color="blue">manufacturing</font> practices</td>
    </tr>
    <tr>
      <td><font color="blue">The FDA     </font><font color="blue">periodically revises</font> the good <font color="blue">manufacturing</font> practices <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Failure     </font>to <font color="blue">comply with</font> applicable <font color="blue">regulatory</font> <font color="blue">requirements</font> can result in warning     letters, fines, <font color="blue">injunctions</font>, civil penalties, recall or seizure of products,     total or partial suspension of production, refusal of the <font color="blue">government</font> to     grant marketing <font color="blue"><font color="blue">application</font>s</font> and <font color="blue">criminal prosecution</font></td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">cannot predict</font> the extent of <font color="blue">government</font> <font color="blue">regulations</font> or the     impact of new <font color="blue">government</font>al <font color="blue">regulations</font> that may result in a delay in the     <font color="blue">development</font>, production and marketing of our products</td>
    </tr>
    <tr>
      <td>As such, we may be     required to incur <font color="blue">significant</font> costs to <font color="blue">comply with</font> current or <font color="blue">future laws</font> or     <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Our  ability  to  <font color="blue">generate revenues</font> is <font color="blue">affected by</font> the <font color="blue">availability</font> of     <font color="blue">reimbursement</font> on our product, and our ability to <font color="blue">generate revenues</font> will be     diminished if we fail to obtain an <font color="blue">adequate level</font> of <font color="blue">reimbursement</font> for our     <font color="blue">product from</font> <font color="blue">third party</font> payors</td>
    </tr>
    <tr>
      <td>In <font color="blue">both domestic</font> and <font color="blue">foreign markets</font>, the sale of our <font color="blue">product will depend</font> in     part on the <font color="blue">availability</font> of <font color="blue">reimbursement</font> from <font color="blue">third party</font> payors such as     state and federal <font color="blue">government</font>s (for example, under <font color="blue"><font color="blue">Medicare and Medicaid </font>    </font>programs in the <font color="blue">United States</font>) and private insurance plans</td>
    </tr>
    <tr>
      <td>In certain     <font color="blue">foreign markets</font>, the pricing and                                         14       _________________________________________________________________    [68]Table <font color="blue">of <font color="blue">Contents       </font></font><font color="blue">profitability</font> of our <font color="blue">product generally</font> is subject to <font color="blue">government</font> controls</td>
    </tr>
    <tr>
      <td>In     the <font color="blue">United States</font>, there have been, and we expect there <font color="blue">will continue</font> to be,     a number of state and <font color="blue">federal proposals</font> that limit the amount that state or     federal <font color="blue">government</font>s will pay to reimburse the cost of drugs</td>
    </tr>
    <tr>
      <td>We believe the     increasing  <font color="blue">emphasis on managed care</font> in the <font color="blue">United States</font> has and will     continue to <font color="blue">put pressure on</font> the price and usage of our product, which may     also impact <font color="blue">product sales</font></td>
    </tr>
    <tr>
      <td>Further, when a <font color="blue">new therapeutic</font> is approved, the     <font color="blue">reimbursement</font> status and rate of such a product is uncertain</td>
    </tr>
    <tr>
      <td>In addition,     current <font color="blue"><font color="blue">reimbursement</font> policies</font> for our <font color="blue">existing product may</font> change at any     time</td>
    </tr>
    <tr>
      <td>Changes in <font color="blue">reimbursement</font> or our failure to obtain <font color="blue">reimbursement</font> for     our <font color="blue">products may</font> reduce the demand for, or the price of, our product, which     could result in lower <font color="blue">product sales</font> or revenues, thereby weakening our     <font color="blue">competitive position</font> and <font color="blue"><font color="blue">negatively</font> impacting</font> our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In the <font color="blue">United States</font>, proposals have called for substantial changes in the     <font color="blue">Medicare  </font>and  Medicaid programs</td>
    </tr>
    <tr>
      <td>Any such changes <font color="blue">enacted may</font> require     <font color="blue">significant</font> reductions from currently projected <font color="blue">government</font> <font color="blue">expenditure</font>s for     these programs</td>
    </tr>
    <tr>
      <td>The Medicare Prescription Drug Improvement Act, enacted in     <font color="blue">December </font>2003, provides for, among other things, an <font color="blue">immediate reduction</font> in     the  <font color="blue">Medicare  </font><font color="blue">reimbursement</font>  rates  for  many <font color="blue">drugs administered</font> in a     physician’s office</td>
    </tr>
    <tr>
      <td>The Medicare Act, as well as other changes in <font color="blue">government</font>     <font color="blue">legislation</font> or regulation or in private <font color="blue">third party</font> payors’ policies toward     <font color="blue">reimbursement</font> for our products, may reduce or eliminate <font color="blue">reimbursement</font> of our     products’ costs</td>
    </tr>
    <tr>
      <td>Driven <font color="blue">by budget concerns</font>, Medicaid <font color="blue">managed care systems</font>     have <font color="blue">been implemented</font> in several states and <font color="blue">local metropolitan areas</font></td>
    </tr>
    <tr>
      <td>If the     <font color="blue">Medicare and Medicaid </font>programs implement changes that restrict the access of     a <font color="blue">significant</font> population of patients to <font color="blue">innovative medicines</font>, the market     <font color="blue">acceptance</font> of these <font color="blue">products may</font> be reduced</td>
    </tr>
    <tr>
      <td>We are unable to predict what     impact the <font color="blue">Medicare Act </font>or other future <font color="blue">legislation</font>, if any, relating to     <font color="blue">third party</font> <font color="blue">reimbursement</font>, will have on our <font color="blue">product sales</font></td>
    </tr>
    <tr>
      <td>To <font color="blue">facilitate</font> the <font color="blue">availability</font> of our product for Medicaid patients, we have     <font color="blue">contracted with</font> the Center for <font color="blue">Medicare and Medicaid </font>Services</td>
    </tr>
    <tr>
      <td>As a result,     we pay quarterly rebates <font color="blue">consistent</font> with the <font color="blue">utilization</font> of our product by     individual states</td>
    </tr>
    <tr>
      <td>We <font color="blue">also give <font color="blue">discounts</font> under contract on purchases</font> or     <font color="blue">reimbursement</font>s of <font color="blue">pharmaceutical</font> products by certain other federal and state     agencies and programs</td>
    </tr>
    <tr>
      <td>If these <font color="blue">discounts</font> and <font color="blue">rebates become burdensome</font> to     us and we are not able to sell our <font color="blue">product through</font> these channels, our net     <font color="blue">sales <font color="blue">could decline</font></font></td>
    </tr>
    <tr>
      <td>Our business is subject to changing regulation of <font color="blue">corporate governance</font> and     public  <font color="blue">disclosure</font>  that  has <font color="blue">increased both</font> our costs and the risk of     <font color="blue">noncompliance</font></td>
    </tr>
    <tr>
      <td>Because our <font color="blue">common stock</font> is <font color="blue">publicly traded</font>, we are subject to <font color="blue">certain rules</font>     and <font color="blue">regulations</font> of federal, state and <font color="blue">financial market exchange entities</font>     <font color="blue">charged with</font> the protection of investors and the oversight of companies     <font color="blue">whose securities</font> are <font color="blue">publicly traded</font></td>
    </tr>
    <tr>
      <td>These entities, including the Public     Company Accounting Oversight Board, the SEC and the American Stock Exchange,     have  recently  issued  new  <font color="blue">requirements</font> and <font color="blue">regulations</font> and continue     developing <font color="blue">additional</font> <font color="blue">regulations</font> and <font color="blue">requirements</font> in response to recent     corporate  scandals  and  laws  enacted  by Congress, <font color="blue">most notably</font> the     Sarbanes-Oxley Act of 2002</td>
    </tr>
    <tr>
      <td>Our efforts to <font color="blue">comply with</font> these new <font color="blue">regulations</font>     have resulted in, and are likely to continue resulting in, <font color="blue">increased general</font>     and <font color="blue">administrative expenses</font> and diversion of <font color="blue">management</font> time and attention     from revenue-generating <font color="blue">activities</font> to compliance <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>In particular, our efforts to prepare to <font color="blue">comply with</font> Section 404 of the     Sarbanes-Oxley Act and related <font color="blue">regulations</font> for fiscal years ending on or     after July 15, 2007 regarding our <font color="blue">management</font>’s required <font color="blue">assessment</font> of our     <font color="blue">internal control over financial</font> reporting and our in<font color="blue">dependent</font> auditors’     <font color="blue">attestation</font> of that <font color="blue">assessment</font> will require the <font color="blue">commitment</font> of <font color="blue">significant</font>     financial  and <font color="blue">managerial resources</font></td>
    </tr>
    <tr>
      <td>Although <font color="blue">management</font> believes that     ongoing efforts to assess our <font color="blue">internal control over financial</font> reporting will     enable  <font color="blue">management</font> to provide the required report, and our in<font color="blue">dependent</font>     auditors to provide the required <font color="blue">attestation</font>, under Section 404, we can give     no assurance that <font color="blue">such efforts will</font> be completed on a timely and successful     basis to enable our <font color="blue">management</font> and in<font color="blue">dependent</font> auditors to provide the     required report and <font color="blue">attestation</font> in order to <font color="blue">comply with</font> SEC rules <font color="blue">effective</font>     for us</td>
    </tr>
    <tr>
      <td>Moreover, because the new and changed laws, <font color="blue">regulations</font> and standards are     subject  to varying <font color="blue">interpretations</font> in many <font color="blue">cases due</font> to their lack of     <font color="blue">specificity</font>, their <font color="blue">application</font> in <font color="blue">practice may evolve over</font> time as new     guidance is provided by <font color="blue">regulatory</font> and <font color="blue">governing bodies</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">evolution may</font>     result in <font color="blue">continuing uncertainty</font> regarding <font color="blue">compliance matters</font> and <font color="blue">additional</font>     <font color="blue">costs necessitated by ongoing revisions</font> to our <font color="blue">disclosure</font> and governance     practices</td>
    </tr>
    <tr>
      <td>15       _________________________________________________________________    [69]Table <font color="blue">of <font color="blue">Contents       </font></font>Our stock price has a history of <font color="blue">volatility</font>, and an <font color="blue">investment</font> in our stock     <font color="blue">could decline</font> in value</td>
    </tr>
    <tr>
      <td>The price of our <font color="blue">common stock</font>, like that of other specialty <font color="blue">pharmaceutical</font>     companies, is subject to <font color="blue">significant</font> <font color="blue">volatility</font></td>
    </tr>
    <tr>
      <td>The price per share of our     <font color="blue">common stock</font> ranged in value from dlra0dtta38 to dlra1dtta23 during the <font color="blue">two year period</font>     ended <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>Any number of events, both internal and external to     us,  may  continue  to  affect our stock price</td>
    </tr>
    <tr>
      <td>These include, without     <font color="blue">limitation</font>, our quarterly and <font color="blue">yearly revenues</font> and earnings or losses; our     ability to acquire and market appropriate <font color="blue">pharmaceutical</font>s; announcement by     us or our <font color="blue">competitors</font> regarding product <font color="blue">development</font> efforts, including the     status  of  <font color="blue">regulatory</font>  approval  <font color="blue"><font color="blue">application</font>s</font>;  the  outcome of legal     <font color="blue">proceedings</font>, including claims filed by us against <font color="blue">third parties</font> to enforce     our patents and claims filed by <font color="blue">third parties</font> against us relating to patents     held by the <font color="blue">third parties</font>; the launch of <font color="blue">competing products</font>; our ability to     obtain  <font color="blue">product from</font> our contract <font color="blue">manufacture</font>rs; the resolution of (or     failure to resolve) disputes with collaboration partners and corporate     <font color="blue">restructuring by us</font></td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">product liability</font> lawsuits</font> are <font color="blue">successfully</font> brought against us or we     become  subject to other forms of <font color="blue">litigation</font>, we may incur substantial     <font color="blue">liabilities</font> and costs and may be required to limit <font color="blue">commercialization</font> of our     products</td>
    </tr>
    <tr>
      <td>Our business <font color="blue">will expose us</font> to <font color="blue">potential liability risks</font> that are inherent     in the testing, <font color="blue">manufacturing</font> and marketing of <font color="blue">pharmaceutical</font> products</td>
    </tr>
    <tr>
      <td>The     use of any <font color="blue"><font color="blue">drug candidate</font>s</font> ultimately developed by us or our <font color="blue">collaborators</font>     in <font color="blue">clinical trials</font> may expose us to <font color="blue">product liability</font> claims and possible     <font color="blue">adverse publicity</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">risks will expand</font> for any of our <font color="blue"><font color="blue">drug candidate</font>s</font>     that receive <font color="blue">regulatory</font> approval for <font color="blue">commercial sale</font> and for those products     we <font color="blue">currently market</font></td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability insurance</font> for the <font color="blue">pharmaceutical</font>     industry is <font color="blue">generally expensive</font>, if <font color="blue">available at</font> all</td>
    </tr>
    <tr>
      <td>We currently have     <font color="blue">product liability</font> insurance for claims up to dlra10dtta0 million</td>
    </tr>
    <tr>
      <td>However, if we     are  unable  to  maintain <font color="blue">insurance coverage at</font> acceptable costs, in a     <font color="blue">sufficient amount</font>, or at all, or if we become subject to a <font color="blue">product liability</font>     claim, our reputation, stock price and ability to devote the <font color="blue">necessary</font>     resources to the <font color="blue">commercialization</font> of our <font color="blue">products could</font> be <font color="blue">negatively</font>     impacted</td>
    </tr>
  </tbody>
</table>